Soft Anticholinergic Formulations for Stable Hyperhidrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical anticholinergic agents used for treating hyperhidrosis often exhibit systemic side effects and lack stable, pharmaceutically acceptable formulations with commercially viable shelf-life, limiting their effectiveness and safety.
Innovation Solution
A composition comprising a soft anticholinergic ester analog of glycopyrrolate, formulated with anhydrous ethanol and optional gelling or viscosity-controlling agents, provides a stable and effective topical treatment for hyperhidrosis, minimizing systemic side effects and ensuring long-lasting sweat reduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical anticholinergic agents are administered to treat hyperhidrosis, then sweat reduction is achieved, but systemic side effects occur
Solution Approach 1:
The patent modifies the chemical structure of anticholinergic compounds by converting them from stable forms to soft drug esters that undergo controlled hydrolysis. This parameter change in chemical stability allows the drug to remain active topically for sweat reduction while rapidly degrading into inactive metabolites, preventing systemic accumulation and side effects
Solution Approach 2:
The patent extracts the problematic property of long systemic circulation from traditional anticholinergics by designing soft ester analogs that are specifically engineered to hydrolyze rapidly in aqueous environments, thereby removing the harmful persistent systemic exposure while retaining the desired topical therapeutic effect
2Duration of action of stationary object
If stable formulations of soft anticholinergic esters are developed, then shelf-life is improved, but formulation complexity increases
Solution Approach 1:
The patent employs anhydrous (water-free) formulation as an inert environment that prevents hydrolysis of the soft ester compounds during storage. By eliminating water from the formulation matrix, the unstable ester bonds remain intact, providing commercial shelf-life stability while avoiding the need for complex preservative systems or refrigeration
Solution Approach 2:
The patent accepts that the formulation may have limited stability once exposed to moisture, so it uses simple, inexpensive anhydrous alcohol as a solvent that provides sufficient stability during storage but allows rapid drug release and hydrolysis upon topical application, eliminating the need for complex stabilizing additives
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves significant sweat reduction for up to 48 hours with minimal systemic side effects, maintaining stability and efficacy comparable to glycopyrrolate, while avoiding the need for additional preservatives.
Implementation Method 1
quickly metabolized into their designed-in, inactive metabolite upon entering the systemic circulation
Data Source
AI summary
Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.